At long last luvelta-T is shelved, and Sutro seeks a new focus.
ApexOnco Front Page
Recent articles
The Japanese group licenses sapablursen from Ionis for $280m.
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The group is persevering with Granite, but funds might be hard to come by.
For $850m up front Roche gets to challenge Pfizer.